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The gene RUNX1 at chromosome 21q22 encodes the alpha subunit of Core binding factor (CBF), a heterodimeric
transcription factor involved in the development of normal hematopoiesis. Translocations of RUNX1 are seen in
several types of leukemia with at least 21 identified partner genes. The cryptic t(7;21)(p22;q22) rearrangement
involving the USP42 gene appears to be a specific and recurrent cytogenetic abnormality. Eight of the 9 cases
identified in the literature with this translocation were associated with acute myeloid leukemia (AML), with the
remaining case showing refractory anemia with excess blasts, type 2. Herein, we present a patient with two
preceding years of leukopenia and one year of anemia prior to the diagnosis of AML, NOS with monocytic
differentiation (myelomonocytic leukemia) whose conventional cytogenetics showed an abnormal clone with 5q
deletion. Interphase FISH using LSI RUNX1/RUNXT1 showed three signals for RUNX1. FISH studies on previously
G-banded metaphases showed the extra RUNX1 signal on the short arm of chromosome 7. Further characterization
using the subtelomeric 7p probe showed a cryptic 7;21 translocation. Our case and eight previously reported
leukemic cases with the t(7;21)(p22;q22) appear to share similar features including monocytic differentiation,
immunophenotypic aberrancies (often with CD56 and/or CD7), and a generally poor response to standard induction
chemotherapy. About 80% of these cases had loss of 5q material as an additional abnormality at initial diagnosis or
relapse. These findings suggest that t(7;21) may represent a distinct recurrent cytogenetic abnormality associated with
AML. The association between the t(7;21) and 5q aberrancies appears to be non-random, however the pathogenetic
connection remains unclear. Additional studies to evaluate for RUNX1 partner genes may be considered for AML
patients with RUNX1 rearrangement and 5q abnormalities; however knowledge of the prognostic implications of this
rearrangement is still limited.
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Gene fusion and chromosomal abnormalities play vital
roles in tumorigenesis, including hematologic malignan-
cies [1]. More than 100 fusion genes have been reported
in acute myeloid leukemia (AML) [2]. Many of these
fusion genes involve the translocation of Runt-related
transcription factor 1 (RUNX1), also known as acute mye-
loid leukemia 1 protein (AML1) [3]. The gene RUNX1 at
chromosome 21q22 encodes the alpha subunit of core
binding factor (CBF), a heterodimeric transcription factor
involved in the development of normal hematopoiesis.
At least 21 partner genes of RUNX1 have been identi-* Correspondence: ctirado@mednet.ucla.edu
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acute lymphoblastic leukemia (ALL) [4,5], acute mye-
loid leukemia (AML), and myelodysplastic syndromes
(MDS). In AML, the t(8;21)(q22;q22) is the most fre-
quent translocation involving RUNX1. In contrast, the
much rare t(7;21)(p22;q22) involving a rearrangement
with the USP42 gene, is cryptic, but appears to be a spe-
cific and recurrent cytogenetic abnormality.
The deletion of all or part of long arm of chromosome
5 (del(5q)) is a recurrent abnormality in AML and MDS
patients. While the association between del(5q) and AML
are still unclear, a deletion of 1.5 Mb region at 5q31.1
flanked by genes IL-9 and EGR-1 has been reported to be
related with AML [6]. In addition, del(5q) is mostly part ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Aspirate smear, Wright-Giemsa, 100× – cluster of
intermediate-sized blasts with irregular nuclear contours, fine
chromatin with 1–2 nucleoli, and relatively abundant cytoplasm
with occasional small vacuoles and rare azurophilic granules.
Rare small lymphocytes and plasma cells are intermixed.
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it more difficult to reveal its significance.
In this study, we describe a new AML case with a
cryptic t(7;21)(p22;q22) and chromosome 5q abnormal-
ity. The case reported here shares the common features
with the few other cases reported in the literature, sug-
gesting that the t(7;21)(p22;q22) may represent a distinct
entity in AML.
Clinical presentation
The patient is a 57-year-old female who was referred for
hematology consult after presenting with a two-year his-
tory of chronic leukopenia with progression to include
anemia of several months duration. A bone marrow
biopsy was performed, revealing approximately 24% my-
eloblasts by immunohistochemistry, with the blasts ex-
pressing monocytic differentiation with aberrant CD56
expression by flow cytometry. She was diagnosed with
AML, and was referred to an academic center for in-
patient chemotherapy and possible transplant. Following
evaluation, she was placed on Revlimid therapy as op-
posed to induction chemotherapy for about 5 months
without improvement or significant deterioration of her
blood counts. She was referred to our institution to be
evaluated for allogenic stem-cell transplantation. A
repeat bone marrow biopsy (about 6–7 months post diag-
nosis) confirmed persistent AML, and the patient was
started on 7 + 3 AML induction (Cytarabine 320 mg IV
continuous days 1–7, Idarubicin 19 mg IV on days 3–6).
A day 16 repeat bone marrow biopsy showed persistent
presence of abnormal myeloblasts. Biopsy about 6 weeks
following induction therapy showed remission with no ex-
cess or abnormal myeloblasts. She completed consolida-
tion chemotherapy with high-dose cytarabine (3 gm/m2
IV q 12 hours on days 1, 3, 5 for 6 doses), and recently
had a successful allogenic stem-cell transplant.
Materials and methods
Histologic methods
Particle smears and touch preparations were prepared
upon receipt of specimen, air dried, and stained with
Wright-Giemsa. Trephine biopsy and aspirate clot sections
were fixed in B5 and buffered formalin, respectively. Fol-
lowing fixation, tissues were paraffin-embedded, and 4-μm
thick sections were cut and stained with hematoxylin-
eosin.
Flow cytometry
A WBC suspension is created from the bone marrow
aspirate sample using bulk lysing with BD Pharmlyse
(ammonium chloride base) and PBS wash. 6-Color custom
cocktails (FITC/PE/PerCPCy5.5/APC/APCH7/V450 fluoro
chrome format) for immunophenotyping were manu-
factured by the CTT group of Becton Dickinson. Theantibody staining and fixation include a 15 minute in-
cubation in the dark, PBS washing, and resuspension &
fixation with 1% paraformaldehyde. The Becton Dick-
inson FACSCanto II (3-laser) flow cytometer with BD
FACSDiva Software were used for event acquisition,
and FCS Express Version 3.00.0821 (DeNovo Software,
Los Angeles, CA) was used for analysis.Cytogenetic studies
Conventional chromosome analysis was performed on
bone marrow cells using standard cytogenetic techniques
and G-banding. A total of 20 metaphase cells were ana-
lyzed. Karyotypes were prepared using Applied Imaging
CytoVision software and described according to the guide-
lines of International System for Human Cytogenetic
Nomenclature (ISCN, 2013) [7].Fluorescence in situ hybridization (FISH)
FISH studies were performed on both interphase nuclei and
previously G-banded metaphases from the patient’s bone
marrow sample. Interphase FISH probes included: EGR1/
D5S23-D5S721, D7S486 (7q31)/CEP 7, CEP 8 (D8Z2)/
D20S108 (20q12), PML/RARA Dual Color (DC) Dual
Fusion (DF), BCR/ABL DC, DF, EVI1 Tri-color (3q26),
CBFB DC (16q22), MLL DC (11q23) Break Apart and
RUNX1T1/RUNX1 (ETO/AML1) DC DF probe. Meta-
phase FISH on previously G-banded slides included
RUNX1T1/RUNX1 (ETO/AML1) DC DF probe, TelVy-
sion 7p, 7q and 14q probe (subtelomeric cocktail). All
the probes were from Abbott Molecular (Des Plaines,
Illinois 60018).
Figure 2 Trephine biopsy, Hematoxylin & Eosin, 100× – Cluster
of blasts with background small lymphocytes, plasma cells,
and histiocytes.
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Morphology and immunophenotypic findings
The bone marrow biopsy demonstrated a hypocellular
marrow with increased blasts representing about 25% of
the cellular marrow elements (Figures 1 and 2). Back-
ground hematopoiesis was suppressed and left-shifted,Figure 3 Blast immunophenotype, flow cytometry histograms (closed
immunophenotypic markers with aberrant expression of CD7 and CDbut did not show morphologic evidence of dysplasia.
Immunophenotyping of the abnormal blasts by flow cy-
tometry (Figure 3) showed expression of CD10 (partial),
CD11b (partial), CD13, CD14 (partial), CD15 (partial),
CD16 (partial), intracytoplasmic CD22 (partial), surface
CD22 (partial), CD34 (partial), CD36 (partial), CD38,
CD56 (partial), CD64 (partial), CD117 (partial), HLA-
DR (bright), and Myeloperoxidase (partial). Features of
myelomonocytic dysmaturation were present.
Cytogenetic analysis
Chromosome analysis of the bone marrow revealed add-
itional material of unknown origin at 5q13. This unbalanced
rearrangement characterized as “add” (ISCN, 2013) led to
partial deletion of 5q in 5 of the 20 metaphase cells exam-
ined. The initial karyotype was described as: 46,XX,add(5)
(q13) [5]/46,XX[15] (Figure 4a). This finding was confirmed
by the concurrent interphase FISH study (Figure 4b).
FISH
The RUNX1/RUNXT1 DC DF interphase FISH exhibited
three green signals for RUNX1 (Figure 5). FISH studies on
previously G-banded metaphases showed that the extra
RUNX1 signal was on the short arm of chromosome 7
(Figure 6). Further characterization using the subtelomericgate) – Note expression of myeloid and monocytic
56.
Figure 4 (a) Karyotype on the bone marrow aspirate showing an additional material of unknown origin attached on 5q leading to 5q
loss. (b) Interphase FISH with two signals of 5p15.2 region (green) and one signal of EGR1 (orange) suggests loss of 5q.
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cryptic 7;21 translocation (Figure 7). Based on the meta-
phase FISH study, the final karyotype of the bone marrow
was characterized as: 46,XX,add(5)(q13)[5]/46,XX[15].ish t
(7;21)(p22;q22)(RUNX1+; VIJyRM2185+).
Discussion
In this study, we describe a new case of semi-cryptic t
(7;21)(p22;q22) involving the RUNX1 gene and the loss
of chromosome 5q in an AML patient. First reported byPaulsson et al. in AML [8], only 9 cases of t(7;21)(p22;
q22) have been reported in to date (Table 1) [2,8-12]. Lit-
erature review shows that t(7;21) is a recurrent cytogenetic
abnormality in AML [9-11]. The incidence rate of this ab-
normality varies among reports but is relatively low; Giguere
et al. [2] reported approximately 1% in 95 AML patients,
and Jeandidier et al. reported 0.75% in 397 cases of AML.
We compared our case with the other reported t(7;21)
(p22;q22) cases (Table 1) [2,8-11]. Of all the 9 reported t
(7;21)(p22;q22) cases, eight were diagnosed as AML, and
Figure 5 Interphase FISH with RUNX1/RUNXT1 dual color dual
fusion probe showed three signals of RUNX1 (green) and two
signals of RUNXT1 (orange).
Figure 7 FISH with TelVysion 7p (green, on the sub-telomere
region of 7p), 7q (orange, on the sub-telomere region of 7q)
and chromosome 14 (yellow and aqua) showing one green
signal of 7p on der(21) and the der(7) is missing a green signal.
Two normal chromosomes 14 are seen as indicated by the signal
pattern (one yellow and one aqua signals on two normal
chromosomes 14 respectively).
Ji et al. Experimental Hematology & Oncology 2014, 3:8 Page 5 of 8
http://www.ehoonline.org/content/3/1/8one as an MDS (RAEB-2). In all reported AML patients
with t(7;21)(p22;q22) including our current case, the
common features in these patients include: 1) Aberrant
CD56 expression (8/9 patients) and aberrant CD7 expres-
sion (6/9 patients). No patients had expression of CD19,
which is commonly seen in t(8;21) [13,14]. 2) Myelomono-
cytic or monocytic differentiation was common (6/9), and
3/9 patients did not show maturation or showed minimal
differentiation. 3) Patients responded poorly to the standard
induction chemotherapy. 4) Eight of the 9 patients had loss
of chromosome 5q at the initial diagnosis or at relapse.
CD56 expression is seen in about 25% [15,16] of AML
cases with t(8;21) (q22;q22), and is generally associated
with poor prognosis [16]. Meanwhile, CD7 is expressed
in about 30% of AML cases and its positivity is linked
with poor prognosis in myeloid malignancies [17]. The tFigure 6 FISH with LSI RUNX1/RUNXT1 probe showing the
green signals of RUNX1 on der(7), der(21) and normal
chromosome 21, respectively. Two normal orange of RUNXT1 are
seen on the chromosomes 8.(7;21)(p22;q22) AML cases had CD56 and CD7 positive
rates higher than what has been reported in general
AML cases, and these patients had an overall poor re-
sponse to standard chemotherapy (Table 1).
One of the genes located on chromosome 5q is riboso-
mal protein S14 (RPS14), which is essential for the main-
tenance of normal erythroid progenitor cells [10]. Loss
of chromosome 5q causes haploinsufficiency of RPS14
[18]. Boultwood et al. [19] hypothesized that this haploin-
sufficiency may be related with failure of erythropoiesis. In
our case report, the patient had a history of anemia for one
year, and the karyotype showed loss of chromosome 5q.
We speculate that the anemia in this patient is related with
haploinsufficiency of RPS14, however, this speculation
would need to be validated by further molecular testing.
As previously noted, deletion of 5q is a common cyto-
genetic abnormalities in 8 of the 9 patients with t(7;21)
(p22;q22). The high incidence of t(7;21)(p22;q22) found
together with del(5q) suggest that this combination is a
non-random abnormality. Many questions need to be
answered, including: Why does this combination happen
with such a high frequency? What is the etiology? What
is the significance of these aberrancies in relation to
AML? Although a recent large scale cooperative study
of 514 MDS patients showed that 5q deletion with add-
itional cytogenetic abnormalities is a marker of poor
prognosis [20], additional study is needed for this com-
bination in AML. While we cannot provide further
experimental evidence, we think one possibility is that
two (or more) functionally redundant genes were dis-
rupted by the t(7;21)(p22;q22) and del(5q) respectively.
Subsequently, the affected cells would have lost important
Table 1 Reported cases with t(7;21)(p22;q22)




Index case 1 Monocytic 56 yo, F CD7, CD56 Cytarabine/Idarubicin “7+3” Yes Yes CR 51 days s/p induction. Completed
consolidation and recently underwent
unrelated SCT
Paulsson, et al. [8] 2 Minimal
differentiation
7 yo, M Partial CD56 NOPHO-AML-93 protocol No Yes (at relapse) Relapse at 5 years with successful
re-induction
Foster, et al. [9] 3 Monoblastic/
Monocytic
68 yo, M NA MidAC No Dead at 5 years from unrelated illness






54 yo, M CD2, CD7, CD22, CD56 GOELAMS No Yes Relapse at 23 months, DOD
6 Monoblastic/Monocytic 33 yo, M CD7, CD56 SHG AML96 No Yes CR after salvage chemo and allogenic
transplant, alive at 36 months
7 Myelomonocytic 39 yo, M CD22, CD56 Cytarabine/Idarubicin No Yes Partial response to salvage chemo, dead
of bacterial sepsis within months of dx
Gindina, et al. [12] 8 Myelomonocytic 13 yo, M CD7, CD56, CD71 AIE/HAM No Yes Remission after consolidation chemo,
No long-term survival data reported
Panagopoulos,
et al. [11]
9 Without maturation 52 yo, F CD7, CD56 “Standard induction” NA Yes In remission at nine months post dx,
no long-term survival data reported
MDS
Foster, et al. [9] 10 RAEB-2 (17% blasts) 68 yo, F NA Mylotarg, Daunorubici,
Clofarabine
Yes No Remained in remission post maintenance
chemotherapy
Abbreviations: NA not available, MIDAC Mitoxantrone and cytarabine, GOELAMS groupe ouest-est des Leucémies et Autres Maladies du Sang 2001 AML protocol, DOD died of disease, SHG AML96 süddeutsche
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or DNA repair.
All previous reports about the t(7;21)(p22;q22) re-
arrangement have detected a RUNX1-USP42 fusion
protein. It is reasonable to assume that our case also has
the associated RUNX1-USP42 fusion protein, although we
did not pursue the exact partner of RUNX1 in this report
due to the limited specimen. RUNX1 is a vital regulator of
hemopoiesis [21]. Various hemopoietic signaling mole-
cules, growth factors, and transcription factors are regu-
lated by RUNX1 [22]. RUNX1 translocation is a recurrent
feature in many AML and MDS patients, and numerous
translocation partners have been described. RUNX1
rearrangment’s leukemogenicity lies in the retention of
RUNX1’s DNA binding “Runt homology domain” (RHD)
domain, and associated loss of its transactivation do-
main. The resultant fusion protein acts as a dominant
negative inhibitor of wild-type RUNX1 in transcription
activation [11,22].
While most studies focus on RUNX1, ubiquitin spe-
cific peptidase 42 (USP42) may also play an important
leukemogenic role in t(7;21)(p22;q22) cases. USP42, be-
longing to the ubiquitin-proteasome system (UPS), is a
deubiquitinating enzyme (DUB). The process of ubiquiti-
nation and deubiquitination decides the fate of many
proteins, many of which are related with cell cycle re-
gulation, DNA repair, and differentiation. USP and the
DUBs contain many potential drug targets for the treat-
ment. USP42 itself was reported to increase the stability
of p53 [23]. We propose that RUNX1-USP42 fusion pro-
tein loses wild type USP42 function and decreases the
stability of p53. Further studies to characterize the in-
volvement of USP42 in our case were not possible due
to insufficient sample.
In conclusion, we report a new case of AML with a
cryptic t(7;21)(p22;q22) and chromosome 5q abnormality.
To the best of our knowledge, this represents one of the
few AML patients with this genetic aberrancy. Review of
the literature showed that our case shares many common
features with other reported cases, which suggests that
t(7;21)(p22;q22) may represent a new distinct entity in
AML.
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